# BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity

> **NCT05051631** · NA · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 1071 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** Intervention plus 12 months maintenance
- **OTHER:** Intervention plus 10 months maintenance
- **OTHER:** Intervention plus 8 months maintenance
- **OTHER:** Intervention plus 6 months maintenance
- **OTHER:** Intervention plus 4 months maintenance

## Key facts

- **NCT ID:** NCT05051631
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-09
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 1071 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05051631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05051631, "BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05051631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*